Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a lung cancer case study, Dr. Rimm uses this instrumentation to evaluate tumor infiltrating lymphocytes.
Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a breast cancer case study, Dr. Rimm uses this instrumentation in her immune-oncology research.
Cancer researchers now can visualize more of a tumor than ever before using PerkinElmer’s Phenoptics Quantitative Pathology Research Solutions. In a melanoma case study, Dr. Tumeh uses this instrumentation to develop biomarkers in his cancer immunology research.
A new generation of high-content imaging systems such as the PerkinElmer Operetta CLS High Content Imaging System and Harmony High Content Imaging and Analysis Software are helping scientists to blaze new trails in cancer drug therapy.
Researchers offer evidence of the importance of epithelial-to-mesenchymal transition (EMT) in the progression of chronic kidney disease.
PerkinElmer's Phenoptics™ quantitative pathology research system helped researchers reveal a predictive biomarker for Merkel cell carcinoma.
Using TIBCO Spotfire® visualization tools, PerkinElmer demonstrates this analytical versatile software in the study of infectious diseases.
PerkinElmer-GIS Centre for Precision Oncology leverages genome expertise and leading edge imaging instrumentation to develop new cancer therapies.
In a medical first, UNC researchers engineer and record skin cells becoming cancer killers using PerkinElmer’s IVIS system.
Monash Institute of Pharmaceutical Sciences is working to develop an inhaled oxytocin treatment for PPH, excessive bleeding after childbirth that kills an estimated 140,000 women a year.